Thank you for your Alois Society membership and your support in the fight against Alzheimer’s disease.

This has been an exciting time for the Alzheimer’s Association and the Alzheimer’s movement, as we achieved tangible results and gained momentum toward our mission goals. Together, we:

- Grew the number of people participating in Walk to End Alzheimer’s®, our largest signature event. At more than 600 locations nationwide, nearly 500,000 people raised $76 million for the cause.
- Thanks to the efforts of the Alzheimer’s Association and our advocates, Congress passed a historic funding increase of $350 million for Alzheimer’s research in the FY2016 budget, bringing total funding to nearly $1 billion per year.
- We provided services and support to 3.6 million people affected by the disease, including answering more than 312,000 calls via our 24/7 Helpline. We built participation in early-stage programs by 59 percent, creating greater engagement with families at a critical time when decisions and plans need to be made.
- We released the 2015 Alzheimer’s Disease Facts and Figures report, which revealed that less than half of seniors diagnosed with Alzheimer’s or their caregivers report being told of the diagnosis by a health care provider, driving the national conversation about this disease forward while raising critical awareness.
- Earned recognition from Web of Science of Thompson Reuters as the global nonprofit with the greatest impact on Alzheimer’s research. Since its inception in 1982, our International Research Grants Program has awarded more than $350 million to more than 2,300 scientific investigations, with a recent focus on supporting scientists early in their careers.

To learn about the other programs, services and studies that you and your fellow Alois Society members have helped to make a reality, please visit alz.org.

A Message from Harry Johns, Alzheimer’s Association President and CEO

The Alzheimer’s Association is the world’s leading voluntary health organization in Alzheimer’s care, support and research. Our mission is to eliminate Alzheimer’s disease through the advancement of research, to provide and enhance care and support for all affected, and to reduce the risk of dementia through the promotion of brain health. Our scale is a worldwide network. Alzheimer’s disease affects 55 million people worldwide and is the third leading cause of death, after heart disease and cancer.

The Alois Society is named after Alois Alzheimer, the pioneering physician whose investigations in 1906 were the first steps toward understanding the disease that now bears his name.

As a member of the Alois Society, you provide the financial leadership needed to help the Alzheimer’s Association advance innovative and groundbreaking research into the causes and treatment of Alzheimer’s disease.

Your support also helps us to increase awareness of Alzheimer’s disease among the public, provide a host of special programs to caregivers and serve as the leading voice for Alzheimer’s disease advocacy.

Your membership in this critically important and elite family of donors sends a strong message of help and hope to the surging number of people affected by Alzheimer’s. To learn more, visit alz.org/AloisSociety. Thank you!
Aim to improve care for people with dementia, understand Alzheimer's disease, and further our knowledge of brain health and disease prevention.

Recent critical research includes studies on topics like gender-based differences in Alzheimer's risk and prevalence; the effect of educational differences in Alzheimer's risk; new predictive tests that may help identify Alzheimer’s at an earlier stage; and multi-pronged approaches to treatment, including medications and lifestyle changes.

More than 5 million Americans are living with this cruel and fatal disease, and this number is increasing dramatically. With your help, we can continue to make significant strides and provide hope for all of those affected by Alzheimer's disease.

Your commitment makes a difference

Welcome to the Alois Society, an exclusive group of supporters whose vision and dedication provide leadership in the fight Alzheimer's disease and other dementias—now and well into the future.

More than 5 million Americans are living with this cruel and fatal disease, and this number is increasing dramatically. With your help, we can continue to make significant strides and provide hope for all of those affected by Alzheimer's disease.

We deeply appreciate your support and have been working tirelessly to honor your significant strides and provide hope for all of those affected by Alzheimer's disease.

A member of the Alois Society, you are helping us make groundbreaking progress in advocacy as we fight for additional funding of Alzheimer's research, support and care initiatives.

Recently, the Alzheimer’s Association successfully lobbied before Congress for the Alzheimer’s Accountability Act, a formal process to ensure that Congress is led by scientific guidance from the nation’s top scientists when it makes funding decisions for Alzheimer’s research. This professional judgment budget establishes how much funding is needed to reach the first goal set by the National Plan to Address Alzheimer’s Disease to prevent and treat Alzheimer’s by 2025.

Because of our historic victory with the Alzheimer’s Accountability Act, we are now closer than ever to receiving an increase in funding for Alzheimer’s research. This increase will go far to help us discern methods of treatment, prevention and, one day, a cure.

The National Institutes of Health recommended a $323 million increase in its first professional judgment budget to address Alzheimer’s in fiscal year 2017.

“Congress has told us they want to hear directly from the nation’s top scientists … they have heard from those experts that Alzheimer’s disease warrants reft and significant investment,” said Harry Johns, president and CEO of the Association. “This objective research funding estimate is critical as Congress continues their work to revere the historic underfunding of Alzheimer’s disease of the past several decades.”